In the specialized field of biochemical research, the exploration of synthetic macrocyclic compounds has opened new doors for understanding molecular interactions. Among these, peptide CBO-P11 stands out as a subject of significant interest for researchers focusing on protein-ligand binding and signaling pathway modulation. As someone who follows advancements in laboratory-grade research compounds, I have found the technical profile of this 17-amino acid cyclic peptide to be remarkably precise for controlled experimental environments.
Technical Specifications and Structural Profile
Peptide CBO-P11 is formally recognized as a 17-amino acid cyclic peptide, often referred to as cyclo-VEGI. Its molecular architecture is derived from residues 79-93 of the Vascular Endothelial Growth Factor (VEGF). With a molecular formula of C94H145N29O25S and a molecular weight of 2113.43 g/mol, it serves as a hig A comprehensive analysis ofCBO-P11, a macrocyclicpeptideinhibitor of Vascular Endothelial. Growth Factor (VEGF), reveals its distinct efficacy profile hly specific tool in proteomics.
When analyzing the VEGF inhibitor CBO-P11, one must note Structure and Inhibitory Effects on Angiogenesis and its capacity to mediate binding to VEGFR-2. Structurally, the molecule is designed to block the interaction between growth factors and their receptors. This specificity is why the agent is used as targeting ligand for tumor angiogenesis in controlled *in vitro* models. Researchers often utilize this compound to study the mechanisms by which a molecule controls the biological activity of VEGF, essentially acting as a structural probe.
Experimental Applications and Utility
In my review of laboratory practices, I have observed that peptide CBO-P11 is frequently deployed in analytical biochemistry. It is primarily used for Phosphorylation & Dephosphorylation applications, where researchers track protein activation states. By inhibit by L Zilberberg·2003·Cited by 160—It appears that a.17-amino acid cyclic peptide (CBO-P11), herein designated cy- clo-VEGI, inhibits very efficiently the binding of VEGF to its receptor VEGFR2.Read more ing specific binding events, this cyclic peptide CBO-P11 allows for a clearer observation of downstream signaling cascades, such as the downregulation of Akt3.
For those looking to buy highly pure CBO-P11, it is critical to verify the CAS No: 612096-46-5. High-quality samples are typically provided as a lyophilized powder, which requires storage at -20°C to maintain stability. Its solubility in DMSO makes it compatible with various buffer systems used in high-throughput proteomic approaches.
Advancements in Peptide Research
The field of peptides is currently undergoing a transformation, with researchers moving to explore AI-driven design, novel delivery methods & targeted therapy innovations. The P11 peptide is a classic example of how a small, synthetic macrocyclic structure can be func by F Rossi·Cited by 2—Our biological evaluations highlight an anti- angiogenic capacity of CBO-P23M and CBO-P23M dimer comparable to that ofCBO-P11 peptidewhich was previously.Read more tionalized—for instance, by coupling it to nanoparticles—to enhance its utility as a research probe.
Furthermore, the 17-amino acid cyclic peptide (CBO-P11) has been instrumental in studies demonstrating how a compound is able to inhibit the interaction between the growth factor and Join experts in Peptides & Emerging Drug Conjugates at OPT Congress 2026.Explore AI-driven design, novel delivery methods & targeted therapy innovations. its receptor. Because it is a VEGF Inhibitor, CBO-P11 acts as a molecular "blocker," providing a baseline against which other novel angiogenesis inhibitors are measured. Whether examining technical guides on synthesis or reviewing proteomics data, the consistency of this molecule remains a benchmark in the study of receptor-ligand dynamics.
Conclusion
The study of peptide CBO-P11 continues to provide valuable insights into the regulation VEGF Inhibitor, CBO-P11, is a macrocyclic peptide derived from residues 79-93 of VEGF. Mediates VEGF binding to VEGFR-2. Blocks VEGF165 binding to VEGFR1 and 2 Read more of vascular endothelial growth factors. As a research-grade tool, its ability to interfere with specific binding sites makes it an indispensable asset for those investigating complex protein signaling. By maintaining strict handling protocols—such as proper storage and precise solvent preparation—investigators can ensure the reliab by YM Kulkarni·2015·Cited by 40—We therefore used theVEGF inhibitor CBO-P11as a therapeutic measure within our high-throughput proteomic approach to delineate important angiogenesis-related Read more ility of their data when using this potent inhibitor. The ongoing evolution of P11-based research highlights the enduring importance of well-characterized cyclic peptides in modern biochemical discovery.